Menlo bags $119M IPO on promise of ex-Merck drug
That IPO window appears to remain propped open. Menlo Therapeutics, a low-profile biotech with a single asset picked up from Merck for $1 million upfront …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
